Notice of Annual General Meeting

RNS Number : 3526L

Novacyt S.A.

13 May 2022

 

Novacyt S.A.

("Novacyt" or the "Company")

Notice of Annual General Meeting

Paris, France and Camberley, UK - 13 May 2022 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on 21 June 2022 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] ; [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

[phone]

[e-mail] / [e-mail]  

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com  

 

END

 

 

NOAFLFFREVIFLIF